A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of LY3819469 in Adults With Elevated Lipoprotein(a)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of LY3819469 in Adults With Elevated Lipoprotein(a)
The main purpose of this study is to determine the efficacy and safety of LY3819469 in adults with elevated lipoprotein(a). The study will lasts about 20 months.
Inclusion Criteria:
Participants must be at least 40 years old at the time of signing the informed consent.
Participants with Lp(a) ≥175 nmol/L at screening, measured at the central laboratory
Participants on the following medications according to local practice must be on a stable regimen for at least 4 weeks prior to screening and randomization and expected to remain on a stable regimen through the end of the Treatment and Assessment Period:
Male and/or Female
Exclusion Criteria:
Have a history or presence of an underlying disease, or surgical, physical, medical, or psychiatric condition that, in the opinion of the investigator, would potentially affect participant safety within the study or interfere with participating in or completing the study or with the interpretation of data.
Any of the following, or other events indicating unstable medical condition in the opinion of the investigator, within 3 months of randomization:
Have, in the 6 months prior to day 1, uncontrolled Type 1 or Type 2 diabetes.
Have uncontrolled hypertension
Ciudad Autónoma de Buenos Aire, Buenos Air C1027AAP, Argentina
Chuo-ku, Tokyo 103-0027, Japan
Shinjuku-ku, Tokyo 160-0004, Japan
Shinjuku-ku, Tokyo 160-0008, Japan
Culiacán, Sinaloa 80230, Mexico
Bucharest, Bucharest 011053, Romania